<<I see from this year's annual report that one
of the goals of Gene Logic is to begin using
the Flow-Through chip--screening for leads.
I think I asked this once before, but I will
again: Where does Gene Logic get the library
of compounds from which to find candidates?>>
The chip is still in development. We have not done any screening yet.
If we were to successfully develop the chip for this purpose, the customer (i.e., pharmaceutical company) would be expected to supply the library.
The paragraph above contains forward-looking statements about the potential use of the Flow-thru Chip(TM) microarray in screening for lead compounds. Such statements reflect management's current view of future events. Actual results may differ materially from these projections because of a number of factors, including risks related to technological challenges, competition, the cost-effectiveness of the technology, and the degree to which pharmaceutical companies use gene expression information in their drug discovery programs. These risk factors and others are more fully described in the company's Annual Report on Form 10-K for the year ended December 31, 1998, and other documents filed with the Securities and Exchange Commission.
Steve Push
Vice President, Corporate Communications
Gene Logic Inc.
Note: I participate occasionally on this message board as an official company spokesperson. Because of time constraints, however, I cannot respond to all questions. My failure to comment on or respond to someone else's message implies neither agreement nor disagreement with the information in that message. Past messages that I have posted may now contain out-of-date information. To be certain that you have the latest information about Gene Logic, please read recent press releases, SEC filings, and other documents available on our Web site (http://www.genelogic.com). |
